Updates in MRD in Hematologic Malignancies - prIME Oncology
eMonograph
eMonograph

Updates in MRD in Hematologic Malignancies

The What, When, and Why of Minimal Residual Disease

Not a member of My prIME? Join now for instant access.

Gain insights on the emerging role for minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). Using multimedia components, this engaging activity provides updates on optimal timing and strategies to assess MRD and expert perspectives on the appropriate interpretation and integration of MRD results in treatment decision-making.

Interactive Presentation

Interactive Presentation

CME

CME

1.0 AMA PRA Category 1 Credit(s)

Animation

Animation

Release Date

Release Date

Apr 12, 2019

Expiration Date

Apr 12, 2020

  • Jacqueline C. Barrientos, MD, MSZucker School of Medicine at Hofstra/Northwell
    Lake Success, New York, United States
  • Shaji Kumar, MDMayo Clinic
    Rochester, Minnesota, United States
  • Alexander E. Perl, MDHospital of the University of Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Eunice Wang, MDRoswell Park Cancer Institute
    Buffalo, New York, United States

Learn about the science and technology behind MRD as well as how MRD is being use (or may be used in the future) in managing ALL, AML, CLL and MM.

This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of hematologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Discuss current and emerging technologies used to measure MRD in hematologic malignancies
  • Assess clinical trial data that analyze the use of MRD assessment in the management of MM, CLL, ALL, and AML
  • Optimize the use of MRD assessment in managing patients with hematologic malignancies, including MM, CLL, ALL, and AML

This educational activity is supported by a grant from AbbVie, Adaptive Biotechnologies, and Amgen.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1 hour

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Barrientos has disclosed that she has received consulting fees from Genentech, Gilead, Janssen, and Pharmacyclics/AbbVie. She has also performed contracted research for Pharmacyclics/AbbVie. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Kumar has disclosed that he has received consulting fees with no personal payments from AbbVie, Amgen, Celgene Corporation, Genentech, Janssen, KITE, Medimmune, Merck, and Takeda. He has received consulting fees with personal payment from Adaptive and Oncopeptides. He has also performed contracted research for AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, KITE, Medimmune, Merck, Novartis Oncology, Roche-Genentech, Sanofi, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Perl has disclosed that he has received consulting fees from AbbVie, Actinium, Agios, Astellas, Daiichi Sankyo, Jazz, and Takeda. He has performed contracted research for Actinium, Astellas, Bayer, Daiichi Sankyo, and FujiFilm. He has performed contracted research for his institution for Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wang has disclosed that she has been on speaker bureaus for Astellas, Jazz, and Novartis Oncology. She has an advisory role for AbbVie, Agios, Amgen, Celyad and Pfizer. She is leading clinical trials at her institute funded by Agios, Amgen, Arog Pharmaceuticals, Astellas, Daiichi, Eisai/H3B Biosciences, Forma Therapeutics, Immunogen, Incyte, Ono Pharmaceuticals, Oscotec, Pfizer, Stemline Therapeutics, Tolero, and Trovagene.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director) – worked on non–CME certified projects in the last 12 months supported by Pfizer
  • Tristin Abair, PhD (medical writer) – worked on non–CME certified projects in the last 12 months supported by AbbVie Inc; Astellas Pharma Inc.; Bayer AG; Novartis International AG; and Jazz Pharmaceuticals
  • Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.